Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHari Chandrika MaddineniSPSridevi R. Pitta

Discussion

Loading...

Member takes

Overview

Observational cohorts reveal venetoclax-obinutuzumab improves progression-free survival and patient-centered outcomes over continuous BTKi treatment in CLL.

Key Points

  • Evaluate real-world effectiveness and patient-centered outcomes of fixed-duration versus continuous first-line therapy in CLL.
  • Comprehensive database search for studies comparing fixed-duration and continuous therapies in CLL.
  • Included observational cohorts published from January 2010 to June 2025.
  • Primary outcomes assessed included time to next treatment, progression-free survival, and overall survival.
  • Observation of 8,783 patients with CLL across four studies included in the review.
  • Time to next treatment significantly favored venetoclax-obinutuzumab over BTKis (87.1% vs. 75.3%).
  • Two-year follow-up indicated 86.3% of VenO patients remained treatment-free or alive, showing strong effectiveness.

Cite This Study

Maddineni et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6bdhttps://doi.org/10.1182/blood-2025-7437
View Full Paper
Ask AI
Bookmark
Share